GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » EV-to-FCF

Advagene Biopharma Co (ROCO:6709) EV-to-FCF : -14.61 (As of May. 25, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Advagene Biopharma Co's Enterprise Value is NT$1,135.45 Mil. Advagene Biopharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-77.70 Mil. Therefore, Advagene Biopharma Co's EV-to-FCF for today is -14.61.

The historical rank and industry rank for Advagene Biopharma Co's EV-to-FCF or its related term are showing as below:

ROCO:6709' s EV-to-FCF Range Over the Past 10 Years
Min: -39.1   Med: 0   Max: 0
Current: -14.34

ROCO:6709's EV-to-FCF is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 8.36 vs ROCO:6709: -14.34

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Advagene Biopharma Co's stock price is NT$23.60. Advagene Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-1.830. Therefore, Advagene Biopharma Co's PE Ratio for today is At Loss.


Advagene Biopharma Co EV-to-FCF Historical Data

The historical data trend for Advagene Biopharma Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co EV-to-FCF Chart

Advagene Biopharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -15.58 -38.23 -31.74 -11.56 -16.40

Advagene Biopharma Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.74 - -11.56 - -16.40

Competitive Comparison of Advagene Biopharma Co's EV-to-FCF

For the Biotechnology subindustry, Advagene Biopharma Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advagene Biopharma Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advagene Biopharma Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Advagene Biopharma Co's EV-to-FCF falls into.



Advagene Biopharma Co EV-to-FCF Calculation

Advagene Biopharma Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1135.447/-77.697
=-14.61

Advagene Biopharma Co's current Enterprise Value is NT$1,135.45 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advagene Biopharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-77.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advagene Biopharma Co  (ROCO:6709) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Advagene Biopharma Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=23.60/-1.830
=At Loss

Advagene Biopharma Co's share price for today is NT$23.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advagene Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-1.830.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Advagene Biopharma Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Advagene Biopharma Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Advagene Biopharma Co (ROCO:6709) Business Description

Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co (ROCO:6709) Headlines

No Headlines